New Launch20 May 2026, 03:14 pm
ShailyPen Neo™ Device Tech Gets Regulatory Approval
AI Summary
Shaily Engineering Plastics Ltd announces its strategic partner Orbicular Pharmaceutical Technologies, in partnership with its Customer, has launched a generic version of Semaglutide injection in Canada, incorporating Shaily’s proprietary spring-driven ShailyPen Neo™ pen platform. The product is commercially available in India since March 2026 and has received USFDA Tentative Approval. ShailyPen Neo™ is a variable and fixed dose platform offering compatibility with ISO-standard 3 mL cartridges.
Key Highlights
- ShailyPen Neo™ secures USFDA Tentative Approval, Health Canada Notice of Compliance, and Indian Regulatory Approval.
- Generic Semaglutide injection launched in Canada using ShailyPen Neo™ platform.
- ShailyPen Neo™ is a spring-driven pen injector compatible with ISO-standard 3 mL cartridges.
- Shaily responsible for design, development, manufacturing, and supply of device components.
Price Impact
More from SHAILY